Sook buys EXEL 4.21: Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc.
NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. ...
40 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home